The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging
Open accessAbstract
UNLABELLED: (18)F-FDG metabolic tumor volume (MTV) and total glycolytic activity (TGA) have been proposed as potential prognostic imaging markers for patient outcome in human solid tumors. The purpose of this study was to establish whether MTV and TGA add prognostic information to clinical staging in patients with oral and oropharyngeal squamous cell carcinomas (SCCs). METHODS: The Institutional Review Board approved this Health Insurance Portability and Accountability Act-compliant single-institution retrospective study. Forty-five patients with histologically proven oral or oropharyngeal SCC underwent PET/CT for initial cancer staging and were included in the study. MTV was measured using a gradient-based method (PET Edge) and fixed-threshold methods at 38%, 50%, and 60% of maximum standardized uptake value (SUV). The TGA is defined as MTV × mean SUV. Bland-Altman analysis was used to establish the reliability of the methods of segmentation. Outcome endpoints were overall survival (OS) and progression-free survival. Cox proportional hazards univariate and multivariate regression analyses were performed. RESULTS: In Cox regression models, MTV and TGA were the only factors significantly associated with survival outcome after adjusting for all other covariates including American Joint Committee on Cancer (AJCC) stage, with hazards ratio of 1.06 (95% confidence interval, 1.01-1.10; P = 0.006) and 1.00 (95% confidence interval, 1.00-1.01; P = 0.02). The model fit was significantly better when MTV was added to AJCC stage in model I (χ(2) value change, 1.16-6.71; P = 0.01) and when TGA was added to AJCC stage in model II (χ(2) value change, 1.16-4.37; P = 0.04). The median cutoff point of 7.7 mL for primary tumor MTV was predictive of time to OS (log rank P = 0.04). The median cutoff point of 55 g for PET Edge primary tumor TGA was predictive of time to OS (log rank P = 0.08), though the result was not statistically significant. CONCLUSION: Gradient-based segmentations of primary tumor MTV and TGA are potential (18)F-FDG markers for time to survival in patients with oral and oropharyngeal SCC and may provide prognostic information in addition to AJCC stage. These exploratory imaging markers need validation in larger cohort studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., Le, Q.-T., Wakelee, H. A., Graves, E. E., & Loo, B. W. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.05.001 · Cited by 92
Cited by
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Pak, K., Cheon, G. J., Nam, H.-Y., Kim, S.-J., Kang, K. W., Chung, J.-K., Kim, E. E., & Lee, D. S. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.133801 · Cited by 301
“High volumetric parameters were significant variables in predicting a worse prognosis except in 1 study (20).”
BackgroundMethodthe Catalysis TB–Biomarker Consortium, Malherbe, S. T., Shenai, S., Ronacher, K., Loxton, A. G., Dolganov, G., Kriel, M., Van, T., Chen, R. Y., Warwick, J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4177 · Cited by 297
Dosani, M., Yang, R., McLay, M., Wilson, D., Liu, M., Yong-Hing, C. J., Hamm, J., Lund, C. R., Olson, R., & Schellenberg, D. (2019) · Current Oncology · doi:10.3747/co.26.4167 · Cited by 28
Metadata
- Authors
- Dibble, E. H., Lara Alvarez, A. C., Truong, M.-T., Mercier, G., Cook, E. F., & Subramaniam, R. M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-04-09
- Volume
- 53
- Issue
- 5
- Pages
- 709-715
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2142893183
- Cited by
- 217
- References
- 1
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.